Article

IntraLase IPO raises $87M for future growth

Irvine, CA-IntraLase Corp. glided into the public realm in early October with a successful initial public offering (IPO) at the top of its indicated range, selling nearly 7.3 million shares and raising $86.6 million.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
Related Content
Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA
July 26th 2025

Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

NEW DAY trial of ILUVIEN for DME does not meet primary endpoint, post-hoc analysis suggests potential benefits
July 25th 2025

NEW DAY trial of ILUVIEN for DME does not meet primary endpoint, post-hoc analysis suggests potential benefits

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy
July 24th 2025

Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy

Kiora Pharmaceuticals Secures US Patent for KIO-104
July 24th 2025

Kiora Pharmaceuticals Secures US Patent for KIO-104

© 2025 MJH Life Sciences

All rights reserved.